breast-pathology-medchem-2018-keynote

7 / 8

Page 47
Notes:
Journal of Clinical & Experimental Pathology | ISSN: 2161-0681 | Volume 8
Breast Pathology and Cancer Diagnosis
6th World Congress and Expo on
July 25-26, 2018 | Vancouver, Canada
Medicinal Chemistry and Rational Drugs
20 th International Conference on
&
Quality assurance tools to help reduce the diagnostic interpretive error in breast cancer surgical pathology
Objective: To review the frequency and related impact of interpretive errors in anatomic pathology and how quality assurance
(QA) programs measure in their ability to help reduce diagnostic interpretive error in surgical pathology.
Design: From an extensive number of published studies, the rate of major discrepancies identified for cancer patients referred
to another institution occur from 4.6% to 14.7%, depending on type of tissue. However published data indicates the current
intra-lab QA programs ability to detect these discrepancies is only 0.8% to 1.7%. To help understand the cause of this gap, four
formal quality assurance case review programs both inter and intra-lab were reviewed for their ability to satisfy a set of selected
design attributes known to help identify interpretive error. Peer reviewed literature was researched to support claims for each
program percent compliance to the attributes, strengths, drawbacks, and best demonstrated practices were identified.
Results: No program met the selected attribute listing 100%, compliance ranged from 29% (met 2 of 7) to 86% (met 6 of 7) for
each program.
Conclusion: Laboratories should be aware of the limitations of each QA program and take into consideration their case and
pathologist mix and current on-site concerns, select a program with attributes that best match their QA needs. In general,
programs that are standardized, include external review by subspecialist and are performed close to the final sign-out date may
offer the greatest amount of error discovery and potential to positively influence patient outcomes and continuous improvement.
Although this study focused on discordance in cancer related surgical pathology, case review can also be an effective tool in
discovery of all histology/cytology diagnostic and clerical discrepancies.
Biography
Mark Priebe is a subject matter expert in the utilization of whole slide digital imaging for quality assurance of surgical pathology for cancer. Mark has presented on
quality in surgical pathology via podium and posters at multiple scientific meetings and was the Co-Chair for Pathology 16 (Chicago) and Keynote at 5 th International
Meeting on Breast Pathology and Cancer Diagnosis 2018 (Miami), Mark received his undergraduate degree in Medical Technology from Marquette University,
Milwaukee, and advance certification by the ASCP in Immunohematology from the Medical College of Wisconsin, Mark is the co-developer of QualityStar quality
consortium of Omaha Nebraska. QualityStar is an external peer review quality assurance program for Surgical Pathology, approved by the American Board of
Pathology for Part II (SAM) and IV (QA) MOC and multiple other certification/accreditation agencies. The Mission of QualityStar is to support the reduction of major
diagnostic discordance in surgical pathology by 5% (7 to 2%) impacting the lifes of over 80,000 patients annually in North America.
Mark Priebe
Quality Star LLC, USA
Mark Priebe, J Clin Exp Pathol 2018, Volume 8
DOI: 10.4172/2161-0681-C3-050